Published on
01:21 GMT
Dr Bryce on the Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC
"If you really only take away one point [from the study, it] is that on the macro level, all ARPIs performed similarly [in terms of efficacy]. The message for the [oncologist is thatthey] need to think about comorbidities and patient-specific factors …
Source:
OncLive
-
Label Pending
